Randomised trials comparing the efficiency and safety of thrombolytic agents
| Study | No. of patients | Treatment regimens | Mortality, n (%) | Recurrence n (%) | Major haemorrhage, n (%) | Comments | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UK, urokinase, SK, streptokinase, recombinant tissue plasminogen activator, U, units; lb, pound; h, hour | ||||||||||||
| USET phase 242 | 59 | UK 2000 U/lb bolus, 2000 U/lb/h over 12 hours | 4 (7) | 1 (1) | 8 (14) | Angiographic diagnosis, repeated at 24 h showing improved pulmonary flow in UK group but equal at day 5 | ||||||
| 54 | UK 2000 U/lb bolus, 2000 U/lb/h over 24 hours | 5 (9) | 4 (7) | 10 (19) | ||||||||
| 54 | SK 250 000 unit bolus, 100 000 U/h over 24 hours | 5 (9) | 2 (4) | 6 (11) | ||||||||
| Goldhaber et al 198843 | 23 | UK 2000 U/lb bolus, 2000 U/lb/h | 2 (8.7) | 1 (4) | 11 (48) | Perfusion/haemodynamics better at 2 h in rTPA but equal by 24 h. Trend towards more haemorrhage UK | ||||||
| 22 | Rt-PA 100 mg over 2 hours | 2 (8.7) | 0 | 4 (18) | ||||||||
| Meyer et al 199244 | 29 | UK 4400 U/lb bolus, 4400 U/lb/h over 24 hours | 1 (3.4) | 2 (6.9) | 8 (28) | 2 h pulmonary haemodynamics favour rTPA but equal at 12 h | ||||||
| 34 | Rt-PA 80–100 mg over 2 hours | 3 (8.8) | 2 (5.9) | 7 (21) | ||||||||
| Goldhaber et al 199245 | 46 | UK 1 000 000 U over 10 mins, 2 000 000 U over 110 mins | 1 (2) | 3 (6.5) | 6 (13) | No difference at 2 h angiogram or 24 h perfusion scan | ||||||
| 44 | Rt-PA 100 mg over 2 hours | 2 (4.5) | 0 | 9 (20) | ||||||||
| Meneveau et al 199746 | 25 | SK 250000 bolus, 1 000 000 U/h over 12 hours | 1 (4) | 2 (8) | 3 (12) | 2 h pulmonary haemodynamics favour rTPA but no difference by 12 h | ||||||
| 25 | Rt-PA 100 mg over 2 hours | 1 (4) | 0 | 4 (16) | ||||||||
| Meneveau et al 199847 | 43 | SK 1 500 000 U 2 hours | 0 | 1 (2.3) | 3 (7.0) | Identical haemodynamics at 2 h and identical day 2 perfusion scan | ||||||
| 23 | Rt-PA | 0 | 2 (8.7) | 5 (21.7) | ||||||||